Buparvaquone (BW 720C) is a hydroxynaphthoquinone antiprotozoal drug related to atovaquone and parvaquone.

To study whether pretreatment of host cells prior to invasion had any effect on parasite proliferation, confluent HFF grown in 6-well plates are treated with 1?μM buparvaquone in medium for 1?h or 5?h, and controls are exposed to the corresponding amounts of DMSO. Subsequently, the drug-containing medium is removed and monolayers are ished 4 times with Hank's Balanced Salt Solution, and are infected with Nc-Liv tachyzoites in 5?mL medium without any drug or solvent. After 2 days, cells are collected with a cell scraper, centrifuged, ished once more in PBS, and the pellet is stored at ?20?°C prior to quantification of N.?caninum proliferation by N.?caninum-specific real time PCR as outlined below.

Mice: On day 0, all mice are infected by intraperitoneal (i.p.) injection of freshly purified N.?caninum tachyzoites. After 48?h, mice receive BPQ (100?mg/kg) as suspension in corn oil either by i.p. injection of a volume of 100?μl or by oral application of 100?μl by gavage. The control groups obtained the corresponding amount of the solvent only, either i.p. or orally. The treatments are performed 5 times on a daily basis. If not indicated otherwise, mice are inspected twice daily for clinical signs (ruffled coat, apathy, hind limb paralysis) until day 21 post infection (p.i.), at which time they are euthanized.

布帕伐醌, BW 720C, Butalex

DMSO: 3.27 mg/mL (10.02 mM), Sonication is recommended.